FNY Investment Advisers’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25K Hold
250
– – 0.01% 490
2026
Q2
$23K Hold
250
– – 0.01% 516
2026
Q1
$16K Hold
250
– – 0.01% 494
2025
Q4
$19K Hold
250
– – 0.01% 570
2025
Q3
$8K Hold
250
– – ﹤0.01% 840
2025
Q2
$3K Hold
250
– – ﹤0.01% 799
2025
Q1
$3K Hold
250
– – ﹤0.01% 617
2024
Q4
$3K Buy
250
+125
+100% +$1.9K ﹤0.01% 565
2024
Q3
$1K Buy
+125
New +$1.76K ﹤0.01% 622

Other funds holding INBX

FNY Investment Advisers's INBX Position: Q3 2026 in Review

FNY Investment Advisers held its Inhibrx (INBX) position steady in Q3 2026 at 250 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #490.

FNY Investment Advisers first reported a position in INBX in Q3 2024 and has held it in 9 quarters since. 11 funds tracked by Wall St. Rank hold INBX as of Q3 2026.

  • FNY Investment Advisers held 250 shares of Inhibrx worth $25K as of Q3 2026.
  • FNY Investment Advisers left its Inhibrx share count unchanged in Q3 2026.
  • Inhibrx made up 0.01% of FNY Investment Advisers's portfolio in Q3 2026, its #490 holding.
  • FNY Investment Advisers first reported a position in Inhibrx in Q3 2024 and has held it in 9 quarters since.
  • 11 funds tracked by Wall St. Rank held Inhibrx as of Q3 2026.

Based on FNY Investment Advisers's 13F filing for Q3 2026, filed 16 Oct 2026.